AbCellera Biologics Inc. has been profitable from the day it began signing partnerships in 2015 with a platform for novel antibody therapeutics. Now, it is in the process of recording a fourth consecutive year of triple-digit revenue growth, despite only raising $11m in equity funding to date.
The biotech is not currently discovering or developing any drug candidates on its own, but performs high-throughput screening for partners...







